

Anita D'Souza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2918327/publications.pdf>

Version: 2024-02-01

167
papers

4,141
citations

147801

31
h-index

138484

58
g-index

172
all docs

172
docs citations

172
times ranked

5057
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of Race/Ethnicity Reporting in Light Chain (AL) Amyloidosis Clinical Research in the USA. <i>Journal of Racial and Ethnic Health Disparities</i> , 2023, 10, 644-650.	3.2	1
2	Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma. <i>American Journal of Hematology</i> , 2023, 98, 140-147.	4.1	12
3	Development of a conceptual model of patient-reported outcomes in light chain amyloidosis: a qualitative study. <i>Quality of Life Research</i> , 2022, 31, 1083-1092.	3.1	6
4	Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2022, 57, 31-37.	2.4	4
5	Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 83.e1-83.e9.	1.2	9
6	A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients. <i>Bone Marrow Transplantation</i> , 2022, 57, 295-298.	2.4	2
7	Patient-reported outcome measures are associated with health care utilization in patients with transplant ineligible multiple myeloma: a population-based study. <i>Blood Cancer Journal</i> , 2022, 12, 17.	6.2	5
8	Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2901-2912.	1.6	124
9	Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study. <i>Blood Cancer Journal</i> , 2022, 12, 34.	6.2	22
10	Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR TÀcell, and BiTE recipients. <i>Cancer Cell</i> , 2022, 40, 340-342.	16.8	35
11	EPR22-115: Reporting of Race and Ethnicity in AL Amyloid Clinical Trials. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, EPR22-115.	4.9	0
12	MGIP, MGUS, and the PROMISE of meaning in small things. <i>Lancet Haematology</i> , 2022, 9, e315-e317.	4.6	1
13	Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. <i>Blood Advances</i> , 2022, 6, 2466-2470.	5.2	29
14	Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 409.e1-409.e10.	1.2	26
15	Important questions for the malignant hematologist to consider when designing or evaluating a study with patient-reported outcome measures (<scp>PROMs</scp>). <i>European Journal of Haematology</i> , 2022, , .	2.2	1
16	Nutrition perceptions, needs and practices among patients with plasma cell disorders. <i>Blood Cancer Journal</i> , 2022, 12, 70.	6.2	7
17	Rap1A, Rap1B, and Î²-Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol.. <i>Yale Journal of Biology and Medicine</i> , 2022, 95, 45-56.	0.2	0
18	Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	4

#	ARTICLE	IF	CITATIONS
19	Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. <i>Blood Advances</i> , 2022, 6, 3991-3995.	5.2	5
20	Socioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	3
21	A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3) Tj ETQq1 1 0.7843141gBT /Over	10.7	14
22	Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy. <i>American Journal of Hematology</i> , 2022, 97, 1170-1177.	4.1	3
23	Impact of second primary malignancy post-autologous hematopoietic stem cell transplantation on outcomes of multiple myeloma: A CIBMTR analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8057-8057.	1.6	0
24	Incorporating patient-reported outcome data into a hematopoietic cell transplant survival calculator.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7045-7045.	1.6	0
25	Kinetics of humoral immunodeficiency with bispecific antibody therapy in multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8049-8049.	1.6	0
26	Autonomic nervous system control of multiple myeloma. <i>Blood Reviews</i> , 2021, 46, 100741.	5.7	11
27	Salvage second transplantation in relapsed multiple myeloma. <i>Leukemia</i> , 2021, 35, 1214-1217.	7.2	17
28	Prevalence and significance of sarcopenia in multiple myeloma patients undergoing autologous hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 225-231.	2.4	17
29	African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. <i>Cancer</i> , 2021, 127, 82-92.	4.1	15
30	Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 264.e1-264.e7.	1.2	13
31	Changes in patient-reported outcomes in light chain amyloidosis in the first year after diagnosis and relationship to NT-proBNP change. <i>Blood Cancer Journal</i> , 2021, 11, 29.	6.2	6
32	Bronchoalveolar lavage-based COVID-19 testing in patients with cancer. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 65-70.	0.9	19
33	Racial disparities in patients diagnosed with light chain (AL) amyloidosis. <i>Blood Cancer Journal</i> , 2021, 11, 72.	6.2	8
34	Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2021, 35, 3526-3533.	7.2	13
35	Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 410-422.	1.2	13
36	Laboratory Mice â€œ A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma. <i>Frontiers in Immunology</i> , 2021, 12, 667054.	4.8	2

#	ARTICLE	IF	CITATIONS
37	Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e775-e781.	0.4	0
38	Breaking the Age Barrier: Physicians' Perceptions of Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older Adults. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 617.e1-617.e7.	1.2	14
39	Correlates and Outcomes of Early Acute Kidney Injury after Hematopoietic Cell Transplantation. <i>American Journal of the Medical Sciences</i> , 2021, 362, 72-77.	1.1	4
40	What The Princess Bride Teaches Us About Outcomes in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2423-2425.	1.6	7
41	Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older. <i>Cancer</i> , 2021, 127, 4233-4239.	4.1	8
42	Long term follow up of newly diagnosed multiple myeloma patients treated with pembrolizumab consolidation post-autologous stem cell transplantation. <i>Leukemia Research</i> , 2021, 109, 106648.	0.8	0
43	The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill. <i>Translational Psychiatry</i> , 2021, 11, 58.	4.8	36
44	A Pilot Plant-Based Dietary Intervention in Overweight and Obese Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma- the Nutrition Prevention (NUTRIVENTION) Study. <i>Blood</i> , 2021, 138, 4759-4759.	1.4	1
45	Characteristics Associated with Disparities in Survival between Hispanic and Non-Hispanic White Patients with Multiple Myeloma: A Matched Cohort Study. <i>Blood</i> , 2021, 138, 4091-4091.	1.4	0
46	Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 553-561.	2.0	13
47	Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. <i>Cancer</i> , 2020, 126, 5077-5087.	4.1	47
48	Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2229-2236.	2.0	4
49	Reporting of race and ethnicity at an international haematology conference. <i>British Journal of Haematology</i> , 2020, 191, e107-e109.	2.5	4
50	Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2020, 191, 442-452.	2.5	8
51	Adjuvant doxycycline to enhance anti-amyloid effects: Results from the dual phase 2 trial. <i>EClinicalMedicine</i> , 2020, 23, 100361.	7.1	27
52	Health Care Reimbursement, Service Utilization, and Outcomes among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 805-813.	2.0	7
53	In Reply. <i>Oncologist</i> , 2020, 25, e744-e745.	3.7	0
54	Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2011-2017.	2.0	11

#	ARTICLE	IF	CITATIONS
55	Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1876-1885.	2.0	4
56	Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen. <i>Leukemia and Lymphoma</i> , 2020, 61, 3484-3492.	1.3	5
57	Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e161-e166.	2.0	38
58	Multiple myeloma and COVID-19. <i>Leukemia</i> , 2020, 34, 1961-1963.	7.2	29
59	Trends in the use of therapeutic plasma exchange in multiple myeloma. <i>Journal of Clinical Apheresis</i> , 2020, 35, 307-315.	1.3	4
60	Prevalence of decisional regret among patients who underwent allogeneic hematopoietic stem cell transplantation and associations with quality of life and clinical outcomes. <i>Cancer</i> , 2020, 126, 2679-2686.	4.1	11
61	Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials. <i>Cancer</i> , 2020, 126, 2791-2801.	4.1	6
62	Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1288-1297.	2.0	10
63	The use of PROMIS patient-reported outcomes (PROs) to inform light chain (AL) amyloid disease severity at diagnosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 111-118.	3.0	10
64	Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 893-901.	2.0	13
65	Monoclonal Gammopathies After Renal Transplantation: A Single-center Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e468-e473.	0.4	4
66	Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1312-1317.	2.0	49
67	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. <i>Leukemia</i> , 2020, 34, 3338-3347.	7.2	27
68	Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e177-e182.	2.0	378
69	Initial Results of a Phase I Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 43-44.	1.4	44
70	The Hematologist's Role in Amyloidosis Management: Disease Awareness, Diagnostic Workup, and Practice Patterns. <i>Blood</i> , 2020, 136, 28-29.	1.4	2
71	Maintenance Use Is More Important Than the Choice of Bortezomib-Based Triplet Induction in Newly Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 36-37.	1.4	0
72	Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2019, 12, 10-14.	0.9	23

#	ARTICLE	IF	CITATIONS
73	Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 210-215.	3.0	2
74	Baseline patient-reported outcomes in light-chain amyloidosis patients enrolled on an interventional clinical trial. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 87-88.	3.0	2
75	<p>Untangling the clinical and economic burden of hospitalization for cardiac amyloidosis in the United States</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 431-439.	1.9	13
76	Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 56.	6.2	15
77	Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals. <i>JAMA Network Open</i> , 2019, 2, e196476.	5.9	12
78	Patient Reported Outcomes Have Arrived: A Practical Overview for Clinicians in Using Patient Reported Outcomes in Oncology. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2291-2301.	3.0	61
79	An updated single center experience with plerixafor and granulocyte colony–stimulating factor for stem cell mobilization in light chain amyloidosis. <i>Journal of Clinical Apheresis</i> , 2019, 34, 686-691.	1.3	3
80	Importance of Assessing Patient-Reported Outcomes With Salvage Autologous Transplantation in Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1598-1600.	1.6	1
81	A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1492-1497.	2.0	23
82	Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1099-1106.	2.0	12
83	Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. <i>Oncologist</i> , 2019, 24, 1253-1258.	3.7	16
84	Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 827-833.	2.0	23
85	Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 683-688.	2.0	18
86	Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 335-342.	2.0	20
87	Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e33-e38.	2.0	10
88	Busulfan, Melphalan, and Bortezomib Compared to Single Agent High-Dose Melphalan As a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Long Term Follow up of a Novel Conditioning Regimen. <i>Blood</i> , 2019, 134, 2023-2023.	1.4	1
89	Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma. <i>Blood</i> , 2019, 134, 782-782.	1.4	5
90	Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft- <i>versus</i>-host disease: low incidence of lower gastrointestinal tract disease. <i>Haematologica</i> , 2018, 103, 717-727.	3.5	38

#	ARTICLE	IF	CITATIONS
91	Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. <i>Bone Marrow Transplantation</i> , 2018, 53, 1210-1213.	2.4	7
92	Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction. <i>JAMA Oncology</i> , 2018, 4, 343.	7.1	130
93	Peripheral Blood Grafts for T Cellâ€“Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1664-1670.	2.0	36
94	Prevalence of self-reported sleep dysfunction before allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1079-1082.	2.4	5
95	Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 478-485.	2.0	31
96	Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light chain amyloidosis. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 105-111.	0.9	7
97	Longâ€“term outcomes among 2â€“year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large Bâ€“cell lymphoma. <i>Cancer</i> , 2018, 124, 816-825.	4.1	44
98	Mortality and healthcare costs in Medicare beneficiaries with AL amyloidosis. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 1053-1062.	1.4	6
99	Patient-reported distress is prevalent in systemic light chain (AL) amyloidosis but not determined by severity of disease. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 129-134.	3.0	6
100	Recent advances in understanding and treating immunoglobulin light chain amyloidosis. <i>F1000Research</i> , 2018, 7, 1348.	1.6	14
101	Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. <i>Blood Advances</i> , 2018, 2, 933-940.	5.2	27
102	Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. <i>Leukemia Research</i> , 2018, 74, 130-136.	0.8	47
103	Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. <i>BMC Cancer</i> , 2018, 18, 593.	2.6	28
104	Pharmacokinetics of High-Dose Propylene Glycolâ€“Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1610-1614.	2.0	8
105	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2443-2449.	2.0	11
106	Health Care Reimbursement and Service Utilization Among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings. <i>Blood</i> , 2018, 132, 832-832.	1.4	1
107	Monoclonal Gammopathy of Renal Significance. , 2018, 15, .		0
108	Incidence and Predictors of 30-Day Readmissions Following Autologous Hematopoietic Cell Transplantation (auto-HCT) in the US. <i>Blood</i> , 2018, 132, 3544-3544.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Association between Transplant Volumes and 30-Day Readmissions Following Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in the US. <i>Blood</i> , 2018, 132, 617-617.	1.4	0
110	Phase I/II Trial of Bendamustine, Ixazomib and Dexamethasone (BID) in Patients (pts.) with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2018, 132, 1998-1998.	1.4	0
111	Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 165-172.	0.4	17
112	Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. <i>Cancer</i> , 2017, 123, 1828-1838.	4.1	73
113	Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report. <i>Cancer</i> , 2017, 123, 3141-3149.	4.1	65
114	Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1295-1302.	2.0	8
115	Current Use and Trends in Hematopoietic Cell Transplantation in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1417-1421.	2.0	205
116	Response Assessment in Myeloma: Practical Manual on Consistent Reporting in an Era of Dramatic Therapeutic Advances. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1193-1202.	2.0	14
117	Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 305-311.e2.	0.4	6
118	Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis. <i>Contemporary Clinical Trials Communications</i> , 2017, 8, 33-38.	1.1	17
119	Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1955-1960.	2.0	24
120	Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. <i>Blood</i> , 2017, 130, 1156-1164.	1.4	210
121	Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 60-66.	2.0	17
122	Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study. <i>British Journal of Haematology</i> , 2017, 178, 816-819.	2.5	4
123	Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 269-277.	2.0	19
124	Autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (MM) in the era of novel agents: A meta-analysis of phase III randomized controlled trials.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8022-8022.	1.6	0
125	Bendamustine with ixazomib and dexamethasone (BID) for double refractory relapsed multiple myeloma (RRMM): Phase I safety and dosing results.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8012-8012.	1.6	0
126	Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. <i>British Journal of Haematology</i> , 2016, 174, 235-248.	2.5	115

#	ARTICLE	IF	CITATIONS
127	Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 379-386.	0.4	17
128	New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 768-770.	2.0	5
129	Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1893-1899.	2.0	34
130	Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1773-1780.	2.0	7
131	Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation Centers. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 520-527.	2.0	14
132	Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 3141-3149.	1.6	212
133	Signaling Pathways and Emerging Therapies in Multiple Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 156-164.	2.3	20
134	Autologous Hematopoietic Cell Transplantation in Patients with Multiple Myeloma: IMPACT of Age. <i>Blood</i> , 2016, 128, 3456-3456.	1.4	1
135	Trends in Pre- and Post-Transplant Therapies Prior to First Autologous Hematopoietic Cell Transplantation Among Patients with Multiple Myeloma in the United States, 2004-2014. <i>Blood</i> , 2016, 128, 677-677.	1.4	3
136	Association of abnormal molecular markers with clonal plasma cell burden in light chain amyloidosis. <i>Journal of Clinical Oncology</i> , 2016, 34, 8063-8063.	1.6	0
137	Phase I Study of Combination Chemotherapy Plus Ixazomib in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma (ALL). <i>Blood</i> , 2016, 128, 5192-5192.	1.4	0
138	Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis. <i>American Journal of Hematology</i> , 2015, 90, E212-3.	4.1	10
139	Localized Lymph Node Light Chain Amyloidosis. <i>Case Reports in Hematology</i> , 2015, 2015, 1-4.	0.4	3
140	CYP2C19*17 genetic polymorphism—an uncommon cause of voriconazole treatment failure. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 83, 46-48.	1.8	8
141	Impact of Pretransplantation 18F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1605-1611.	2.0	39
142	Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2091-2099.	2.0	55
143	Polyneuropathy improvement following autologous stem cell transplantation for POEMS syndrome. <i>Neurology</i> , 2015, 84, 1981-1987.	1.1	61
144	Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3741-3749.	1.6	163

#	ARTICLE	IF	CITATIONS
145	Post-Transplant Therapy Is More Important Than Induction Regimen Choice in Autologous Hematopoietic Cell Transplantation (AHCT) Recipients for Multiple Myeloma (MM). <i>Blood</i> , 2015, 126, 396-396.	1.4	2
146	A statistical model for predicting neutropenic fever.. <i>Journal of Clinical Oncology</i> , 2015, 33, e18050-e18050.	1.6	0
147	Pharmaceutical amyloidosis associated with subcutaneous insulin and enfvirtide administration. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2014, 21, 71-75.	3.0	74
148	Plerixafor and Abbreviated-Course Granulocyte Colony-Stimulating Factor for Mobilizing Hematopoietic Progenitor Cells in Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1926-1931.	2.0	23
149	Improved Outcomes of Autologous Hematopoietic Cell Transplantation (AHCT) for Light Chain (AL) Amyloidosis: A Center for International Blood and Marrow Transplant Registry (CIBMTR) Study. <i>Blood</i> , 2014, 124, 193-193.	1.4	3
150	Contribution of Chemotherapy Mobilization to Disease Control in Multiple Myeloma Treated with Autologous Transplantation. <i>Blood</i> , 2014, 124, 2447-2447.	1.4	1
151	Plerixafor plus G-CSF (P+G) compared with G-CSF alone (G) for hematopoietic progenitor cell (HPC) mobilization in AL amyloidosis (AL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8606-8606.	1.6	0
152	A Statistical Model for Predicting Neutropenic Fever. <i>Blood</i> , 2014, 124, 5258-5258.	1.4	0
153	Clinically significant anti-A1 in a presumed ABO-identical hematopoietic stem cell transplant recipient: a case report. <i>Transfusion</i> , 2013, 53, 202-205.	1.6	6
154	Waldenström macroglobulinaemia: the key questions. <i>British Journal of Haematology</i> , 2013, 162, 295-303.	2.5	7
155	Low Levels of Interleukin-1 Receptor Antagonist (IL-1RA) Predict Engraftment Syndrome after Autologous Stem Cell Transplantation in POEMS Syndrome and Other Plasma Cell Neoplasms. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1395-1398.	2.0	7
156	Association Between Ipilimumab and Celiac Disease. <i>Mayo Clinic Proceedings</i> , 2013, 88, 414-417.	3.0	58
157	Exploring the amyloid proteome in immunoglobulin-derived lymph node amyloidosis using laser microdissection/tandem mass spectrometry. <i>American Journal of Hematology</i> , 2013, 88, 577-580.	4.1	18
158	Localized Tongue Amyloidosis: A Single Institutional Case Series. <i>Otolaryngology - Head and Neck Surgery</i> , 2013, 149, 240-244.	1.9	28
159	Drug-Induced Amyloidosis: A Proteomic Insight Into 52 Cases. <i>Blood</i> , 2013, 122, 1871-1871.	1.4	1
160	Lymphoma-associated versus lymphocytic-variant hypereosinophilia. <i>Leukemia and Lymphoma</i> , 2012, 53, 2103-2104.	1.3	2
161	Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. <i>Blood</i> , 2012, 120, 56-62.	1.4	133
162	Localized insulin-derived amyloidosis: A potential pitfall in the diagnosis of systemic amyloidosis by fat aspirate. <i>American Journal of Hematology</i> , 2012, 87, E131-2.	4.1	34

#	ARTICLE	IF	CITATIONS
163	The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. <i>Blood</i> , 2011, 118, 4663-4665.	1.4	176
164	Relapse of POEMS Following Autologous Stem Cell Transplantation: A Single Center Experience. <i>Blood</i> , 2011, 118, 3101-3101.	1.4	0
165	Replication of Candidate Gene Single Nucleotide Polymorphisms (SNPs) Previously Reported As Associated with Venous Thromboembolism (VTE). <i>Blood</i> , 2011, 118, 1238-1238.	1.4	0
166	Progressive Multifocal Leukoencephalopathy in Chronic Lymphocytic Leukemia: A Report of Three Cases and Review of the Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, E1-E9.	0.4	44
167	Granulocyte Colony-Stimulating Factor Administration: Adverse Events. <i>Transfusion Medicine Reviews</i> , 2008, 22, 280-290.	2.0	98